Evidence map›Paper›PMID 42404898›Full record

ArticleFrontiers in immunology2026

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study).

Nabil E Omar, Shereen Elazzazy, Anas Hamad, Mohamed Omar Saad, Aya Alasmar, Sahar M Nasser, Maria Benkhadra, Hebatalla M Afifi, Farah I Jibril, Rawan A Dawoud and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Nabil E OmarPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Shereen ElazzazyPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Anas HamadPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Mohamed Omar SaadPharmacy Department, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Aya AlasmarPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Sahar M NasserPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Maria BenkhadraPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Hebatalla M AfifiPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Farah I JibrilPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Rawan A DawoudPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Mohamed S HamidMedical Oncology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Afnan AlnajjarPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Arwa O SahalPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Amaal GuliedPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Hazem ElewaCollege of Pharmacy, QU Health, Qatar University, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2025.1665716.].

Indexed as

biomarkerscancer immunotherapyimmune checkpoint inhibitorsimmune-related adverse eventsoverall survivalprogression-free survivalreal-world data

Identifiers

PMID42404898
PMCPMC13329446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.